Compare TCMD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | BDTX |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 148.1M |
| IPO Year | 2016 | 2020 |
| Metric | TCMD | BDTX |
|---|---|---|
| Price | $30.55 | $2.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $27.00 | $10.60 |
| AVG Volume (30 Days) | 311.1K | ★ 933.0K |
| Earning Date | 02-17-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.66 | N/A |
| EPS | ★ 0.77 | 0.38 |
| Revenue | ★ $311,513,000.00 | $70,000,000.00 |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $39.13 | ★ $7.38 |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $8.61 | $1.20 |
| 52 Week High | $31.13 | $4.94 |
| Indicator | TCMD | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.10 | 44.27 |
| Support Level | $29.11 | $2.56 |
| Resistance Level | $31.13 | $2.83 |
| Average True Range (ATR) | 1.05 | 0.14 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 84.53 | 56.47 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.